A Study of Ocrelizumab in Participants With Relapsing Remitting (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying (DMT)

  • Autoimmune Disorder
  • Multiple Sclerosis (MS)